Date:5/27/2021	
Your Name:J. Alexa Sanders	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Conor Frasier	
Manuscript Title: Genomic Analy	sis of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	_
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Justin Matulay	-
Manuscript Title: Genomic Analysis of Response to Baci	llus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known): TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021		
Your Name:Nury Steuerwald		
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-	Grade Stage 1
Bladder Cancer Patients		
Manuscript number (if known):	TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Jason Zhu	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	_xNone			
	testimony				
7	Support for attending	x_None			
	meetings and/or travel				
8	Patents planned, issued or	x None			
	pending				
	F-1111116				
9	Participation on a Data	x None			
	Safety Monitoring Board or	_ <u></u>			
	Advisory Board				
10	Leadership or fiduciary role	x None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	x None			
	'				
12	Receipt of equipment,	x None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	_xNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

Date:5/27/2021	
Your Name:Claud Grigg	
Manuscript Title: Genomic Analysis of Response to Bacillus Calmette-Guerin (BCG) Treatment	in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known): TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	<u>x</u> None			
	testimony				
7	Support for attending	x_None			
	meetings and/or travel				
8	Patents planned, issued or	_xNone			
	pending				
9	Participation on a Data	_xNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_xNone			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	No.			
11	Stock or stock options	_ <u>x</u> None			
12	Receipt of equipment,	x None			
12	materials, drugs, medical	xNone			
	writing, gifts or other				
	services				
13	Other financial or non-	x None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
			-		

Date:5/27/2021	
Your Name:James Kearns	
Manuscript Title: Genomic Analysis	s of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Stephen Riggs	
Manuscript Title: Genomic Analysis of Response to Ba	acillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known): TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021		
Your Name:Kris Gaston		
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage	<u> 1</u>
Bladder Cancer Patients		
Manuscript number (if known):	TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	<u>x</u> None			
	testimony				
7	Support for attending	x_None			
	meetings and/or travel				
8	Patents planned, issued or	_xNone			
	pending				
9	Participation on a Data	_xNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_xNone			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	No.			
11	Stock or stock options	_ <u>x</u> None			
12	Receipt of equipment,	x None			
12	materials, drugs, medical	xNone			
	writing, gifts or other				
	services				
13	Other financial or non-	x None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
			-		

Date:5/27/2021	
Your Name:Cory Brouwer	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Tucker Burks	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:Aaron Hartman	
Manuscript Title: Genomic Analysis	s of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	<u>x</u> _None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel	X_None	
	meetings and, or traver		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>x</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	Stock of Stock options	_ <u>x</u> None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Dlas	co cummarizo tha abaya ca	nflict of interest in the fall	owing hove
riea	se summarize the above co		owing nox:
L			

Date:5/27/2021	
Your Name:David Foureau	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	Name		
6	Payment for expert testimony	<u>x</u> _None		
	testimony			
7	Support for attending	x None		
,	meetings and/or travel	X_None		
	meetings and, or traver			
8	Patents planned, issued or	x None		
-	pending			
9	Participation on a Data	_xNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_xNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	v None		
11	Stock of Stock options	<u>x</u> _None		
12	Receipt of equipment,	x None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	<u>x</u> None		
	financial interests			
DI-	an annone autono ale en ele en	adliak ad imbanasa in abas 6 H	oute a bass	
riea	Please summarize the above conflict of interest in the following box:			

Date:5/27/2021		
Your Name:Earle Burgess		_
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in I	High-Grade Stage 1
Bladder Cancer Patients		
Manuscript number (if known):	TAU-21-158-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	Name		
6	Payment for expert testimony	<u>x</u> _None		
	testimony			
7	Support for attending	x None		
,	meetings and/or travel	X_None		
	meetings and, or traver			
8	Patents planned, issued or	x None		
-	pending			
9	Participation on a Data	_xNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_xNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	v None		
11	Stock of Stock options	<u>x</u> _None		
12	Receipt of equipment,	x None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	<u>x</u> None		
	financial interests			
DI-	an annone autono ale en ele en	adliak ad imbanasa in abas 6 H	oute a bass	
riea	Please summarize the above conflict of interest in the following box:			

Date:5/27/2021	
Your Name:Peter Clark	
Manuscript Title: Genomic Analysis	of Response to Bacillus Calmette-Guerin (BCG) Treatment in High-Grade Stage 1
Bladder Cancer Patients	
Manuscript number (if known):	TAU-21-158-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_x_None	
4	Consulting fees	<u>x</u> None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	<u>x</u> None		
	testimony			
7	Support for attending	xNone		
	meetings and/or travel			
8	Patents planned, issued or	_ xNone		
	pending			
9	Participation on a Data	_xNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<u>x</u> None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	<u>x</u> None		
	materials, drugs, medical			
	writing, gifts or other			
12	services Other financial or non-	Nama		
13	financial interests	_xNone		
	illialiciai liiterests			
Dloa	Disease summering the above conflict of interest in the following boy.			
rica	Please summarize the above conflict of interest in the following box:			